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ABSTRACT
Immune effector cell (IEC) therapies offer durable
and sustained remissions in significant numbers of
patients with hematological cancers. While these unique
immunotherapies have improved outcomes for pediatric
and adult patients in a number of disease states, as ‘living
drugs,’ their toxicity profiles, including cytokine release
syndrome (CRS) and immune effector cell-associated
neurotoxicity syndrome (ICANS), differ markedly from
conventional cancer therapeutics. At the time of article
preparation, the US Food and Drug Administration
(FDA) has approved tisagenlecleucel, axicabtagene
ciloleucel, and brexucabtagene autoleucel, all of which
are IEC therapies based on genetically modified T cells
engineered to express chimeric antigen receptors (CARs),
and additional products are expected to reach marketing
authorization soon and to enter clinical development in due
course. As IEC therapies, especially CAR T cell therapies,
enter more widespread clinical use, there is a need for
clear, cohesive recommendations on toxicity management,
motivating the Society for Immunotherapy of Cancer
(SITC) to convene an expert panel to develop a clinical
practice guideline. The panel discussed the recognition
and management of common toxicities in the context of
IEC treatment, including baseline laboratory parameters
for monitoring, timing to onset, and pharmacological
interventions, ultimately forming evidence- and
consensus-based recommendations to assist medical
professionals in decision-making and to improve outcomes
for patients.

INTRODUCTION
Immunotherapy is now established as a
fourth pillar of cancer treatment, along
with surgery, radiation, and chemotherapy.
Genetically modified T cells are a novel form
of immunotherapy, characterized by highly
efficient and specific targeting of tumor cells

when compared with checkpoint inhibitors.
At the time of writing this article, three autologous T cell products engineered to express
a chimeric antigen receptor (CAR), tisagenlecleucel, axicabtagene ciloleucel, and brexucabtagene autoleucel,1–3 have been approved
by the US Food and Drug Administration
(FDA) and multiple international health
authorities, based on demonstrated durable
and sustained remissions in a significant
number of patients with relapsed and refractory hematological cancers that formerly had
a dismal prognosis.4–11 All three products
target CD19 and are indicated for the treatment of certain relapsed or refractory (RR)
B cell derived hematological malignancies,
specifically acute lymphoblastic leukemia
(ALL) in children and young adults (tisagenlecleucel) and certain types of aggressive B
cell lymphomas in adults (tisagenlecleucel,
axicabtagene ciloleucel, and brexucabtagene autoleucel). Studies are ongoing for
CD19-
targeted CAR T therapies in additional hematological malignancies, including
mantle cell lymphoma (MCL) and follicular lymphoma.12–14 CAR T cell therapies
targeting antigens other than CD19 are also
rapidly progressing through clinical trials.
The most advanced at the time of publication
are bb2121 (idecabtagene vicleucel)15 16 and
JNJ-4528,17 both of which target B cell maturation antigen (BCMA) and both of which
were granted breakthrough therapy designation by the FDA. At the time of manuscript
publication, more than 500 active clinical
trials investigating CAR T cell therapies for
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cancer were registered with the United States National
Library of Medicine.
As ‘living drugs’, however, the adverse events associated with CAR T cell therapy differ markedly from those
seen with other anticancer regimens. Some of the most
commonly reported toxicities include cytokine release
syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), hemophagocytic lymphohistiocytosis (HLH), and persistent cytopenias and resultant
infections, among others.18–22 During the pivotal phase II
ELIANA trial of tisagenlecleucel in children and young
adults with RR ALL, 73% of patients experienced grade 3
or 4 adverse events, and CRS occurred in 77% of patients.23
Similarly, in the ZUMA-1 trial, which was foundational for
the approval of axicabtagene ciloleucel in adults with RR
large cell lymphoma, 95% of patients experienced grade
3 or higher adverse events, with neurological events
occurring in 64% of patients.24 Although the adverse
events associated with CAR T cells and other immune
effector cell (IEC) therapies are generally manageable
with proper supportive care, the toxicities that do occur
may have rapid onset and can progress to life-threatening
events. Therefore, timely recognition and appropriate
management of these toxicities are vital for safe use of
IEC therapies.
To provide expert guidance to practicing clinicians
using IEC therapies, the Society for Immunotherapy of
Cancer (SITC) established an expert panel dedicated to
IEC-related adverse events. The panel included expert
perspectives from physicians, nursing, and patient advocacy, and considered issues related to patient monitoring, toxicity management, and interventions, with the
goal of preparing recommendations on best practices
for addressing toxicities during treatment with FDA-
approved CAR T cell therapies, as well as other emerging
IEC therapies. Note that familiarity and adherence to
these guidelines do not replace formal accreditation by
the Foundation for the Accreditation of Cellular Therapy
(FACT) or similar regulatory bodies; formal IEC accreditation is strongly recommended by the authors to any
clinical center that plans to offer these therapies to their
patients.
METHODS
Guideline development process
The Institute of Medicine’s (IOM) Standards for Developing Trustworthy Clinical Practice Guidelines were used
as a model to develop the evidence- and consensus-based

recommendations in this article. IOM standards dictate
that guideline development is led by a multidisciplinary
team using a transparent process where both funding
sources and conflicts of interest are readily reported.
Recommendations are based on literature evidence,
where possible, and clinical experience, where appropriate.25 The American Society for Hematology (ASH),
the American Society for Transplantation and Cellular
Therapy (ASTCT), FACT at the University of Nebraska
Medical Center, and the Emily Whitehead Foundation
also provided representatives to serve on SITC’s Immune
Effector Cell-related Adverse Events Expert Panel. For
transparency, a draft of this clinical practice guideline was
made publicly available for comment after journal submission. All comments were considered for inclusion into the
final article. This clinical practice guideline is intended
to provide guidance and is not a substitute for the professional judgment of individual treating physicians.
Evidence and consensus ratings
Panel recommendations were derived from evidence
within the published literature, as well as discussions
during an in-
person consensus meeting and regular
communications and collaborative editing throughout the
manuscript development process along with responses to
a clinical questionnaire that addressed current practices
in the use or recommendation for use of immunotherapy
agents . Evidence supporting panel recommendations
was graded according to the Oxford Center for Evidence-
Based Medicine (OCEBM) Levels of Evidence (2016
version).26 A summary of the OCEBM grading scale may
be found in table 1. The level of evidence (LE) for a given
consensus recommendation is expressed in parentheses
following the recommendation (eg, LE: 1). Recommendations without an associated LE were based on expert
consensus. Consensus was defined as ≥75% agreement
among expert panel voting members.
Conflict of interest policy
As outlined by IOM standards, all financial relationships
of expert panel member that might result in actual,
potential, or perceived conflicts of interest were individually reported. Disclosures were made prior to the onset
of manuscript development and updated on an annual
basis. In addition, panel members were asked to articulate any actual or potential conflicts at all key decision
points during guideline development, so that participants
would understand all possible influences, biases, and/or
the diversity of perspectives on the panel. Although some

Table 1 Summary of The Oxford Levels of Evidence 2
Level 1

Level 2

Level 3

Level 4

Level 5

Systematic review or
meta-analysis

Randomized trial or
observational study
with dramatic effect

Non-randomized
controlled cohort or
follow-up study

Case series, case–
Mechanism-based
control or historically reasoning
controlled study

Adapted from OCEBM (Oxford Center for Evidence-Based Medicine) Levels of Evidence Working Group, “The Oxford Levels of Evidence 2.”26
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degree of relationships without side interests among panel
members are to be expected, those with any significant
financial connections that may compromise their ability
to fairly weigh evidence (either actual or perceived) were
not eligible to participate.
Recognizing that guideline panel members are among
the leading experts on the subject matter under consideration and guideline recommendations should have
the benefit of their expertise, any identified potential
conflicts of interests were managed as outlined in SITC’s
disclosure and conflict of interest resolution policies.
As noted in these policies, panel members disclosing a
real or perceived potential conflict of interest may be
permitted to participate in consideration and decision-
making of a matter related to that conflict, but only if
deemed appropriate after discussion and agreement by
the expert panel.
The financial support for the development of this
guideline was provided solely by SITC. No commercial
funding was received.
GENERAL RECOMMENDATIONS
Product-specific and patient-specific considerations
The onset and severity of therapy-
associated toxicities
typically correspond with the timing and degree of peak
CAR T cell activation and proliferation, as well as underlying disease.19 27–32 Therefore, product and disease-
specific characteristics may place some patients at higher
risk for adverse events. For the approved CAR T cell
therapies, tisagenlecleucel, axicabtagene ciloleucel, and
brexucabtagene autoleucel, structural differences in the
costimulatory domains used to promote T cell activation
have been implicated in the distinct risk profiles reported
in trials to date. Both tisagenlecleucel and axicabtagene
ciloleucel are based on identical antigen recognition
domains (the anti-
CD19 short-
chain variable fragment
FMC63), and both are constructed with identical CD3ζ
T cell signaling domains. Tisagenlecleucel deploys a
CD8α transmembrane region and a 4-1BB costimulatory
domain, while axicabtagene ciloleucel and brexucabtagene autoleucel use a CD28 transmembrane region and
a CD28 costimulatory domain.1 2 CD28-based CARs have
been shown to induce rapid early expansion of T cells
with boosted effector functions, whereas 4-
1BB-
based
CARs cause a more gradual expansion of T cells, shifted
toward a central memory-like phenotype, with a potential
for longer persistence.33 34 The different signaling and
expansion characteristics may explain the earlier timing
of onset of adverse events that has been reported with
CD28-containing CAR T cell therapies.35
In the pivotal ZUMA-1 trial, which led to the approval
of axicabtagene ciloleucel, patients who had undergone
prior allogeneic hematopoietic stem cell transplantation
(allo-HSCT) were excluded, as were patients who had
previously been treated with CAR T cells. Other exclusion
criteria included central nervous system (CNS) involvement or a history of or active CNS disorder, such as seizure,
Maus MV, et al. J Immunother Cancer 2020;8:e001511. doi:10.1136/jitc-2020-001511

cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS
involvement.24 36 In the ZUMA-2 trial that led to approval
for brexucabtagene autoleucel for RR MCL, durable
remissions were attained in the majority of patients, and
the toxicities were similar to those observed with other
CD28 costimulated products.14 37 The JULIET trial, which
was pivotal for the approval of tisagenlecleucel for the
treatment of diffuse large B cell lymphoma (DLBCL), used
similar criteria, with the addition of excluding patients
with class III/IV cardiovascular disability according to the
New York Heart Association Classification and patients
in complete remission—although a history of prior CNS
disease was allowed as long as no active involvement was
present at the time of treatment.38 Subsequent trials have
observed acceptable safety profiles for CAR T cell therapy
in patients with active CNS disease—the phase I TRANSCEND NHL (Non-
Hodgkin Lymphoma) 001 study,
which evaluated lisocabtagene maraleucel, a CD19 CAR
T cell product with defined CD4+/CD8+ composition,
reported only one neurological event among the nine
treated patients with secondary CNS lymphoma.39 40
Current approvals only permit the use of CAR T
cell therapies in patients with more advanced disease.
However, relapse after complete remission is relatively
common in both leukemia and lymphoma, and outcomes
for these patients are generally poor. Based on the known
mechanisms of CAR T cell therapies, patients with very
low disease burden or in complete remission can likely be
treated, potentially with greater safety, given the importance of disease burden as a risk factor for CRS.41–43
Panel recommendations
Treatment decisions should be risk-adapted to take
into account characteristics of individual patients and
products, with earlier and more aggressive intervention warranted with higher risk.
►► Patients who have previously undergone allo-
HSCT,
bispecific T cell engager (BiTE) therapy, anti-CD19
monoclonal antibody (mAb) therapy, and mAbs
against other targets (eg, rituximab) may be treated
with CAR T cells, provided the patient’s disease still
expresses the target antigen (LE: 45).
►► Consideration should be given to the fact that toxicity
and timing of toxicities may differ, depending on the
CAR T cell costimulatory domains or other structural
components (LE: 428).
►► Patients with higher pretreatment disease burden are
at increased risk of severe toxicity.
►► Patient Eastern Cooperative Oncology Group
(ECOG) performance status should be taken into
account before proceeding with CAR T cell therapy,
given the high risk of treatment-associated toxicity.
►► If patients are treated with CAR T cell products in
the outpatient setting, admission should be strongly
considered at the first signs of toxicity, including fever,
hypotension or altered mental status.
►►
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►►

CAR T cell therapies may be appropriate for patients
with stable oncological disease or in CR with high
relapse risk (LE: 444).

Baseline evaluations before starting therapy
The adverse events associated with FDA-approved CAR T
cell therapies may develop suddenly and progress rapidly
to life-
threatening toxicities. As additional targets and
indications expand the available repertoire of IEC therapies, the management of the toxicities associated with
new products may require further modification. Regardless, establishing baseline values for markers of CRS and
neurotoxicity is important so that the caregiving team can
quickly recognize and respond to adverse events at the
earliest possible onset. Several scoring systems have been
developed to monitor baseline mental state, with the
Immune Effector Cell-Associated Encephalopathy (ICE)
score (a modified version of the CARTOX-10 criteria25)
being the most widely used for adult patients.45 For
pediatric patients, the Cornell Assessment of Pediatric
Delirium (CAPD),46 has been validated for evaluating
mental state after CAR T cell therapy.47 Elevated C-reactive protein (CRP) and ferritin levels of >10,000 ng/mL
have been observed in almost every patient who developed severe CRS across public trials. It is important to
note, however, that elevated levels of these markers are
associated with, but not predictive of, toxicity.23 48–52
Panel recommendations
Prior to CAR T cell therapy, treating physicians
should order CRP, ferritin, lactate dehydrogenase
(LDH), complete blood counts, comprehensive
metabolic panel (including Mg/Pho), and transthoracic echocardiogram (TTE) or multigated acquisition (MUGA) scan. Required levels of these clinical
parameters should be established by institutional
standard operating parameters and are often similar
to those required for a patient undergoing autologous
hematopoietic stem cell transplantation (auto-SCT)
(LE: 450 53).
►► All patients should receive baseline neurological evaluations, including ICE scores (for adults) or CAPD
scores (for children<12 years) prior to CAR T cell
therapy (LE: 451).
►► Disease burden should be assessed via imaging and
bone marrow evaluation and/or lumbar puncture, as
appropriate, before initiating CAR T cell therapy.
►► In the case of significant delay between lymphodepletion and infusion, repeating lymphodepleting chemotherapy should be considered after 4 weeks after
initial lymphodepletion.
►►

Infection precautions and prophylaxis
Immunosuppression secondary to lymphodepleting
conditioning is an expected toxicity associated with
CAR T cell therapy. Patients’ immune defenses may be
further compromised by on-t arget killing of B cells by
CD19-targeting CAR T cell products,7 9 54 55 as well as
4

by emerging therapies such as BCMA-d irected CAR T
cells for multiple myeloma. Bacteremia, fungal infections, recurrent urinary tract infections, as well as
viral infections such as influenza, respiratory syncytial
virus, and herpes zoster have all been reported after
CAR T therapy 8 9 24 37 56–60 and reactivation of cytomegalovirus (CMV), Epstein-B arr virus (EBV), and human
herpesvirus 6 are also of concern. In the ELIANA
registration trial of tisagenlecleucel for children
and young adults with RR ALL, infections occurred
in 43% of patients, with 21% experiencing grade 3
and 3% grade 4 infections. In this trial, some patients
with prolonged grade 3 or 4 neutropenia before and
after tisagenlecleucel infusion experienced severe
or fatal infections, including grade 3 human herpesvirus 6 encephalitis. 23 A review of 133 patients with
RR ALL, chronic lymphocytic leukemia (CLL), and
NHL treated with CD19 CAR T cells observed that 26
patients (23%) developed infections within 4 weeks
of infusion and 19 (14%) developed infections within
29–90 days after treatment. Bacterial infections were
most common within the first 28 days, and viral infections occurred more frequently after day 29.58 In the
ZUMA-2 trial, infections of grade 3 or higher occurred
in 32% of the patients, with the most common being
pneumonia (9%).14
Protocols vary from center to center for the routine
administration of prophylactic antibacterial, antiviral,
and antifungal agents for patients undergoing CAR T cell
therapy. The US Centers for Disease Control and Prevention (CDC), together with the Infectious Diseases Society
of America (IDSA) and ASTCT, has published guidelines
for preventing infections in patients undergoing allo-
HSCT,61–63 which apply to all myeloablative transplants
regardless of recipient (adult or child). The published
guidelines do not make a definitive statement on antibacterial prophylaxis, although the prospect of septicemia
is a significant concern for patients undergoing CAR T
cell therapy. A review of 31 centers with experience from
approximately 3400 stem cell transplants found substantial heterogeneity in adherence to published guidelines,
yet a majority of institutions use some form of antiviral
prophylaxis, most often reflecting concern for latent
CMV, herpes simplex virus (HSV), and varicella zoster
virus (VZV) reactivation.64 Additional considerations for
infection prevention in patients undergoing CAR T cell
therapy may be found in a 2020 perspective from Hill and
Seo.65
Patients with cancer are also at high risk of severe
influenza-related complications, with a mortality rate 10
times higher than the general population. A Cochrane
review of six studies with a total of 2275 participants
found evidence, although weak, that the benefits
of influenza vaccination outweigh potential risks in
patients with cancer.45 66–68 However, patients with hematological malignancies frequently present with profound
immunosuppression and cytopenias, both due to disease
and prior therapies, which may limit the efficacy of
Maus MV, et al. J Immunother Cancer 2020;8:e001511. doi:10.1136/jitc-2020-001511
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seasonal influenza vaccines, especially in younger populations.69 70
Reports have emerged of two patients with HIV and
RR DLBCL successfully being treated with axicabtagene
ciloleucel. One patient was non-adherent to antiretroviral drugs prior to initiating therapy and underwent
lymphodepletion with CD4+ cell counts of 53 cells/mm3
and detectable viral load. After CAR T cell infusion,
the patient developed grade 2 CRS and grade 3 ICANS,
both of which resolved after tocilizumab and dexamethasone. The other patient was adherent with antiretroviral therapy (bictegravir, emtricitabine, and tenofovir
alafenamide) with an undetectable HIV viral load and
a CD4 count of 127 cells/mm3. Both patients achieved
complete remissions of their lymphoma after CAR T cell
therapy.71 More experience is needed, however, to determine if HIV-positive patients are at increased risk of infections compared with other patients undergoing CAR T
cell therapy.

Special considerations for the SARS-CoV-2 pandemic
The pandemic caused by the novel coronavirus
SARS-CoV-2 has disrupted almost all aspects of the healthcare system, including cancer care. Treatment plans for
patients undergoing CAR T cell therapies must take into
account potential limitations in hospital resources during
the ongoing pandemic, as well as an utmost concern for
the safety of everyone involved. Because cellular therapy
offers a potentially curative option for patients with otherwise extremely poor prognoses, delaying treatment may
not be an option in many cases. However, adequate staff
and supportive care resources are an absolute prerequisite for proceeding with CAR T cell therapy, and it is
important to ensure that tocilizumab—which, along with
other interleukin (IL)-6-modulating agents, was used as
an investigational intervention for COVID-19—is available for the management of CRS. To assist in clinical
decision making during the pandemic, the panel recommends referring to the interim guidelines published by
the CAR T cell consortium investigators, which discuss
necessary resources, determinants of cell therapy use,
patient selection for B cell non-Hodgkin lymphomas and
B cell ALL, supportive care measures during cell therapy
administration, availability of tocilizumab doses for each
patient during the CRS risk period, and collaborative care
with referring physicians.72

Panel recommendations
The following recommendations are adapted for CAR T
cell therapies from the US CDC, together with the IDSA
and the ASTCT guidelines for preventing infections in
patients undergoing allo-HSCT61 62 67:
►► If a patient is febrile with positive bacterial blood
cultures prior to infusion, appropriate antibacterial
agents should be administered and CAR T cell infusion should be delayed until the patient is afebrile
with negative cultures for at least 48 hours.
►► If a fungal infection is suspected, lymphodepleting
chemotherapy should not be administered until
appropriate antifungals have been initiated and
fungal infection is controlled.
►► If nasal washes are positive for active viral infection
(except for in cases of SARS-CoV-2, see next section)
yet a patient is not in distress, then therapy may
proceed when symptoms improve.
►► All patients should undergo prophylaxis against pneumocystis pneumonia.
►► Prophylaxis for HSV/VZV virus reactivation can be
considered (ie, with low-dose acyclovir).
►► The decision to administer antibacterial, antiviral,
and/or antifungal prophylaxis should be risk-adjusted
based on patient characteristics (ie, pediatric vs adult
patients, prior lines of myelosuppresive therapy, and
infection history).
►► If patients have high-
risk historical features, such
as a history of prolonged steroid use or active high-
dose corticosteroid use, or are undergoing high-
dose lymphodepletion or anticytokine therapy, then
antibacterial and antifungal prophylaxis should be
strongly considered.
►► All patients who develop persistent neutropenia
should have antibacterial and antifungal prophylaxis.
►► Patients with active influenza infections should be
treated with antiviral therapy and infusion held until
resolution of major symptoms.

Grading adverse events
Some of the most frequently seen adverse events associated
with the FDA-approved CAR T cell therapies are CRS, with
rates of occurrence ranging from 37%–93% in patients
with lymphoma24 38 71 and 77%–93% in leukemia,23 73 74
and neurological toxicities, now referred to as ICANS,75
which have been reported in every trial involving CD19
targeted CAR T cells.76 Early trials frequently deployed
different assessment and grading criteria, making it difficult to compare the incidence and severity of CRS and
other adverse events across studies. For example, in
the National Cancer Institute’s Common Terminology
Criteria for Adverse Events (CTCAE) V.4.03, which was
in effect when most CAR T trials began, fever was not
included as a prerequisite for CRS and grading largely
depended on whether infusion was interrupted,77 which
is not applicable for CAR T cells that are normally given
as a single dose over less than 30 min. Several grading
systems, including the Lee Criteria, Penn Criteria, and
CARTOX Criteria, were developed, defining severity by
the requirement for supplemental oxygen and the need
for intravenous fluids and vasopressors.28 59 78–80 Until
recently, neurological events were considered to be a
component of CRS. However, although severe neurotoxicity seems to exclusively affect patients who develop CRS,
the timing can vary greatly, occurring concomitantly or
days after CRS resolves.51 56 In 2019, the ASTCT published
consensus recommendations for separate grading systems
for CRS and ICANS (tables 2–4).75 Advantages to the
ASTCT system are its ease of use, objectivity, solid basis on
criteria that may be immediately assessed by all members
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Table 2 ASTCT CRS consensus grading (adapted from Lee et al/ASTCT, BBMT, 201975)
CRS parameter

Grade 1

Grade 2

Grade 3

Grade 4

Fever*
With

Temperature ≥38°C Temperature ≥38°C Temperature ≥38°C

Hypotension

None

Not requiring
vasopressors

And/or†
Hypoxia

None

Requiring low-flow Requiring high-flow nasal
nasal cannula or
cannula, face mask, non-
blow-by
rebreather mask, or venturi
mask

Temperature ≥38°C

Requiring a vasopressor with or Requiring multiple
without vasopressin
vasopressors (excluding
vasopressin)
Requiring positive pressure (eg,
CPAP, BiPAP, intubation and
mechanical ventilation)

Organ toxicities associated with CRS may be graded according to CTCAE V.5.0, but they do not influence CRS grading.
*Fever is defined as a temperature of ≥38°C not attributable to any other cause. In patients who have CRS who then undergo antipyretic or
anticytokine therapy such as tocilizumab or steroids, fever is no longer required to grade subsequent CRS severity. In this case, CRS grading
is driven by hypotension and/or hypoxia.
†CRS grade is determined by the more severe event: hypotension or hypoxia not attributable to any other cause. For example, a patient with
a temperature of 39.5°C, hypotension requiring one vasopressor, and hypoxia requiring low-flow nasal cannula is classified as grade 3 CRS.
ASTCT, American Society for Transplantation and Cellular Therapy; CRS, cytokine release syndrome.

of a caregiving team, and accuracy in categorizing the
severity of toxicities, although disadvantages include
dependence on the selected interventions for grading.
Retrospective analysis of CRS grading systems demonstrated some alignment between the ASTCT and Lee

criteria, in addition to ASTCT versus Penn criteria, while
there were notable differences between Penn and Lee
criteria. Similarly, the CTCAE neurotoxicity grading and
ASTCT ICANS grading are quite different, with retrospective grading demonstrating key areas of disagreement.81

Table 3 ASTCT ICANS consensus grading for adults (adapted from Lee et al/ASTCT, BBMT, 201975)
Neurotoxicity
domain

Grade 1

Grade 2

Grade 3

Grade 4

ICE score*
Depressed level of
consciousness†

7–9
Awakens
spontaneously

3–6
Awakens to
voice

0–2
Awakens only to tactile
stimulus

0 (patient is unarousable)
Patient is unarousable or requires vigorous
or repetitive tactile stimuli to arouse; stupor
or coma

Seizure

N/A

N/A

Life-threatening prolonged seizure (>5 min),
Any clinical seizure
focal or generalized that repetitive clinical or electrical seizures
resolves rapidly or non- without return to baseline in between
convulsive seizures on
EEG that resolve with
intervention

Motor findings‡

N/A

N/A

N/A

Elevated ICP/
cerebral edema

N/A

N/A

Focal/local edema on
neuroimaging§

Deep focal motor weakness such as
hemiparesis or paraparesis
Diffuse cerebral edema on neuroimaging,
decerebrate or decorticate posturing,
cranial nerve VI palsy, papilledema, or
Cushing’s triad

ICANS grade is determined by the most severe event not attributable to any other cause.
*A patient with an ICE score of 0 may be classified as grade 3 ICANS if awake with global aphasia, but a patient with an ICE score of 0 may
be classified as grade 4 ICANS if unarousable.
†Attributable to no other cause (eg, no sedating medication).
‡Tremors and myoclonus associated with immune effector cell therapies may be graded according to CTCAE V.5.0, but they do not influence
ICANS grading.
§Intracranial hemorrhage with or without associated edema is not considered a neurotoxicity feature and is excluded from ICANS grading. It
may be graded according to CTCAE V.5.0.
ASTCT, American Society for Transplantation and Cellular Therapy; CTCAE, Common Terminology Criteria for Adverse Events; EEG,
electroencephalogram; ICANS, immune effector cell-associated neurotoxicity syndrome; ICE, Effector Cell-Associated Encephalopathy; ICP,
intracranial pressure; N/A, not applicable.
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Table 4 ASTCT ICANS consensus grading for children (adapted from Lee et al.75)
Neurotoxicity
domain

Grade 1

Grade 2

Grade 3

Grade 4

7–9

3–6

0–2

0 (patient is unarousable)

1–8

1–8

≥9

Unable to perform CAPD

Depressed level of
consciousness†

Awakens
spontaneously

Awakens to Awakens only to tactile
voice
stimulus

Unarousable or requires vigorous or
repetitive tactile stimuli to arouse

Seizure (any age)

N/A

N/A

Any clinical seizure focal or
generalized that resolves
rapidly or non-convulsive
seizures on EEG that resolve
with intervention

Life-threatening prolonged seizure
(>5 min), repetitive clinical or electrical
seizures without return to baseline in
between

Motor weakness
N/A
(any age)‡
Elevated ICP/
N/A
cerebral edema (any
age)

N/A

N/A

N/A

Focal/local edema on
neuroimaging§

Deep focal motor weakness such as
hemiparesis or paraparesis
Diffuse cerebral edema on neuroimaging;
decerebrate or decorticate posturing,
cranial nerve VI palsy, papilledema, or
Cushing’s triad

ICE score (age ≥12
years)*
CAPD score (age
<12 years)

ICANS grade is determined by the most severe event not attributable to any other cause. Baseline ICE or CAPD score should be considered
before attributing to ICANS.
*A patient with an ICE score of 0 may be classified as grade 3 ICANS if awake with global aphasia, but a patient with an ICE score of 0 may
be classified as grade 4 ICANS if unarousable.
†Attributable to no other cause (eg, no sedating medication).
‡Tremors and myoclonus associated with immune effector cell therapies may be graded according to CTCAE V.5.0, but they do not influence
ICANS grading.
§Intracranial hemorrhage with or without associated edema is not considered a neurotoxicity feature and is excluded from ICANS grading. It
may be graded according to CTCAE V.5.0.
ASTCT, American Society for Transplantation and Cellular Therapy; CTCAE, Common Terminology Criteria for Adverse Events; EEG,
electroencephalogram; ICANS, immune effector cell-associated neurotoxicity syndrome; ICE, Effector Cell-Associated Encephalopathy; ICP,
intracranial pressure; N/A, not applicable.

As such, interpretation of published CRS and ICANS incidence and severity data must always take into account the
grading system used.
Panel recommendation
The ASTCT consensus system should be used to grade
CRS and ICANS within IEC clinical trials, as well as
after the use of tisagenlecleucel, axicabtagene ciloleucel, and brexucabtagene autoleucel.

►►

CYTOKINE RELEASE SYNDROME
CRS is the most common adverse event reported across
all CAR T cell clinical trials, with an incidence as high as
74%–100% for CD19-directed products.23 27 38 57 59 CRS is
characterized by elevated serum cytokine levels associated
with T cell activation and proliferation. It is considered
an on-target toxicity, arising due to antigen recognition
by IECs, followed by generalized immune activation,
which often includes features of a macrophage activation
syndrome (MAS).7 9 Emerging data suggest that monocytes and macrophages contribute to the development of
CRS.82 83 Initial aspects of CRS pathophysiology, including
the importance of IL-6, have been initially characterized
after CAR T cell therapies,7 50 but different mechanisms
may be implicated with other IEC therapies.
Maus MV, et al. J Immunother Cancer 2020;8:e001511. doi:10.1136/jitc-2020-001511

Several descriptions of treatment strategies for CAR T
cell-associated CRS have been published.5 21 28 31 35 52 59 80 84–87
Although the vast majority of published data has arisen
from experience with tisagenlecleucel and axicabtagene ciloleucel, CRS has also been observed and treated
in emerging CAR T cell products, such as the BCMA-
targeting bb212188 and JNJ-4528. Generally, treatment
of CRS encompasses vigilant supportive care, combined
with therapies intended to break the cycle of aberrant
inflammation.
Laboratory parameters and baseline tests for CRS
Patients with CRS frequently present with elevated serum
CRP and ferritin; however, many standard markers
(including ferritin, CRP, LDH, aspartate aminotransferase, alanine aminotransferase, and creatinine) may
only reach abnormal levels after the onset of clinical
manifestations of CRS.50 Although not typically reported
in clinical charts, the hallmark cytokines of CRS associated
with CD19-directed CAR T therapies are IL-10, IL-6, and
interferon gamma (IFN-γ).21 50 59 78 85 87 89 90 Other markers
of inflammation, including tumor necrosis factor alpha
(TNF-α) and granulocyte macrophage colony-stimulating
factor (GM-CSF), have also been observed at elevated
7
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levels in patient serum.50 85 90 Inhibition of GM-CSF has
also been demonstrated to ameliorate CRS pathology in
xenograft models of leukemia.82 A recent effort to identify risk-associated biomarkers determined that none of
the standard clinical laboratory tests were predictive of
CRS severity. That study developed a three-cytokine signature, based on samples drawn in the first 72 hours, using
IFN-γ, soluble gp130, and soluble IL-1 receptor antagonist, which enabled accurate prediction of which patients
with ALL developed grade 4–5 CRS with 86% sensitivity
(95% CI 57% to 98%) and 89% specificity (95% CI 73%
to 97%). In pediatric patients, a signature based on IFN-γ,
IL-13, and the macrophage inflammatory protein MIP1α
in samples drawn within the first 72 hours after treatment
predicted grade 4–5 CRS with 100% sensitivity (95% CI
72% to 100%) and 96% specificity (95% CI 81% to
100%).50 Because real-time monitoring of cytokine levels
is typically unavailable in most treatment centers, most
grading systems (including the ASTCT consensus grading
system75) are based on clinical observations.
Panel recommendations
In the inpatient setting, complete blood counts,
comprehensive metabolic panel (CMP), Mg, Phos,
CRP, and ferritin should be ordered daily for patients
treated with CAR T cell therapies. Fibrinogen and uric
acid should also be monitored, as required (LE: 350).
►► Neither cytokine levels nor CRP levels have been
validated to be used for clinical decision making for
patients treated with CAR T cell therapies.
►► In patients with prolonged severe CRS (persisting for
72 hours without response to interventions), a cardiac
assessment should be considered as described in the
cardiology section; this may include measurement of
cardiac biomarkers such as troponin or the performance of a TTE (LE: 491).
►► Consider holding G-CSF during CRS. GM-CSF should
be avoided during CRS. Additional recommendations
for the use of growth factors may be found in the cytopenias section (LE: 582 83).
►►

Clinical signs and symptoms for identification of CRS
Per the ASTCT grading system (table 2), fever defines the
onset of CRS, with a temperature ≥38°C not attributable
to any other cause being the sole symptom required for
classification as grade 1. Although fever defines the onset,
if patients are treated with antipyretics or anticytokine
therapy, elevated temperature is not required for subsequent grading, and hypotension and hypoxia are used
to assess severity. At grade 2 CRS, patients present with
hypotension not requiring vasopressors and/or hypoxia
requiring low-flow nasal cannula (≤6 L/min) or blow-by
oxygen. Hypotension requiring a vasopressor (with or
without vasopressin) and/or hypoxia necessitating high-
flow (>6 L/min) nasal cannula, face mask, non-rebreather
or venturi mask defines grade 3 CRS. At grade 4, patients
need multiple vasopressors (again, excluding vasopressin) and/or positive pressure ventilation up to and
8

including intubation. Grade 5 CRS is defined as death in
which another cause is not the principle factor. Resolution is defined by the normalization of all signs and symptoms that led to the diagnosis of CRS. In patients treated
with anticytokine therapy whose temperatures have come
down, CRS may be downgraded as hypotension and
hypoxia improves.75
Beyond fever, hypotension and hypoxia, symptomology
varies widely. CRS symptoms may resemble tumor lysis
syndrome (TLS),90 92 or at higher grades, the clinical
presentation can mimic infection, with malaise, fatigue,
anorexia, myalgias, nausea, vomiting, headache, and
mental status changes.20 21 27 59 75 78 80 87 90 Myalgias and
headaches are extremely common.93 94 Since CRS and
sepsis can coexist, it is very important to presume patients
are infected and managed accordingly while investigating underlying infections in patients undergoing IEC
therapies.
Panel recommendations
►► After CAR T cell infusion, patients should be monitored for CRS and other toxicities for the duration
recommended by the product package insert or study
protocol (typically several weeks).
►► Clinical assessment for CRS should be performed
on an ongoing basis by all members of a patient’s
caregiving team. Grading of CRS should be performed
when a patient’s clinical status changes.
►► Events requiring physician notification should include
deviations from baseline in systolic blood pressure,
heart rate of >120 or <60 beats/min, arrhythmia,
respiratory rate of >25 or <12 breaths/min (or values
outside the normal range in pediatric patients), arterial oxygen saturation of <92% on room air, upward
trend in blood creatinine levels or liver function tests,
tremors or jerky movements in extremities, altered
mental status, and first occurrence of temperature
greater than 38°C, as per the ASTCT definition of
fever.
Timing of onset for CRS
Typically, CRS occurs within 1–2 weeks of cell administration.28 Peak signs and symptoms have been reported
to correlate with maximal CAR T cell proliferation.
For tisagenlecleucel and axicabtagene ciloleucel, the
median time to onset is 2–3 days but can be as early as
within 24 hours, particularly with axicabtagene ciloleucel.
Notably, the time to onset of fever may be earlier in
patients treated with CD28− (ie, axicabtagene ciloleucel
and brexucabtagene autoleucel) compared with 4‐1BB‐
costimulated (ie, tisagenlecleucel) CAR T cell products.35
Most cases of CRS resolve within 7–8 days of the onset of
symptoms, but cases have been documented that persist
more than 30 days.95 The package inserts for Yescarta
(axicabtagene ciloleucel) and Tecartus (brexucabtagene
autoleucel) mandate 7 days of daily monitoring after infusion, whereas Kymriah (tisagenlecleucel) may be administered in the outpatient setting, provided patients are
Maus MV, et al. J Immunother Cancer 2020;8:e001511. doi:10.1136/jitc-2020-001511
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monitored two to three times during the first week after
infusion. Patients or their caregivers need to have a thermometer available to monitor and report any fever. Both
products advise patients to remain within a 2-hour drive
of their treatment center for 4 weeks,1–3 and the clinical
infrastructure and communications need to be clear
and able to expeditiously admit and evaluate a patient
post-CAR T who reports a fever.
Panel recommendations
Product labeling, product-specific risk evaluation and
mitigation strategies (REMS), and trial-specific guidelines should inform the duration and frequency of
monitoring after infusion.
►► In patients deemed to be at high risk of developing
CRS (see next section), inpatient treatment and/or
more frequent monitoring may be warranted.
►► As centers gain more experience administering CAR
T cell therapies, requirements for monitoring may be
modified and outpatient administration may be initiated with the best judgment of the treating physician.
►► Cellular therapy centers should educate patients and
a primary caregiver regarding typical manifestations
of CRS, and about specific actions to take if signs or
symptoms occur.
►►

Increased risk factors for CRS
Across several trials, the most important predictor
of severe CRS after CAR T therapy has been disease
burden.4 31 60 90 96 A retrospective single-center study of
98 children with ALL treated with tisagenlecleucel found
that pretreatment blast count of >25% increased the
risk for hypotension-requiring inotropic support. In the
study, pre-existing cardiac risk factors, systolic or diastolic
dysfunction, or pre-
existing ECG abnormalities were
also risk factors.97 Higher doses of CAR T cells and CARs
containing CD28 costimulatory domains are also associated with increased risk.49 57 95 96
Panel recommendations
High prelymphodepletion disease burden and products that are known to be associated with robust early
expansion of CAR T cells are known risk factors for
severe CRS (LE: 356).
►► Clinical decisions should be based on the expected
course of CRS with the products being used and the
patient being treated.
►►

Management of CRS
Management of CRS often involves direct targeting of
elevated cytokines, especially IL-6. The IL-6 receptor-
blocking antibody tocilizumab was approved by the FDA
in 2017 for the treatment of severe or life-threatening
CAR T-induced CRS.98 However, some protocols advise
administering tocilizumab at earlier onset. A treatment
algorithm developed from experience with the axicabtagene ciloleucel clinical trials advised considering 8 mg/
kg intravenous tocilizumab for persistent (lasting >3
days) and refractory fever in grade 1 CRS, and anti-IL-6
Maus MV, et al. J Immunother Cancer 2020;8:e001511. doi:10.1136/jitc-2020-001511

therapy is recommended for managing hypotension,
hypoxia, and organ toxicity at all grade 2 and higher
cases.28 CRS management for brexucabtagene autoleucel
in ZUMA-2 was similar to previous experience from anti-
CD19 CAR T cells that have CD28 and CD3 ζ costimulatory domains.14 During the tisagenlecleucel clinical
trials, early CRS symptoms were managed with tocilizumab, and corticosteroids were only used as second-
line therapy, in case of refractory hypotension or other
severe CRS symptoms not responsive to the first dose of
tocilizumab.80 Methylprednisolone (2 mg/kg/day) and
dexamethasone (0.5 mg/kg; maximum, 10 mg/dose) are
both commonly used corticosteroids. Some protocols, in
particular those with CD19-directed CAR T cell therapies
with CD28 signaling domains, recommend using dexamethasone for patients with neurological symptoms due
to more efficient penetration of the blood–brain barrier.
Many patients, especially those with ALL or multiple
myeloma, have received corticosteroids as part of their
treatment regimen, and therefore some patients who
experience CRS may have a relative corticosteroid deficiency due to suppression of their hypothalamic–pituitary axis.59 High-dose steroids are not recommended
as a first steroid therapy, as >100 mg daily of prednisone
equivalent may reverse symptoms but risks concurrently
ablating 19-28z CAR T cells.79
Consideration has been given to using tocilizumab
preemptively or as prophylaxis. The Fred Hutchinson
Cancer Research Center, Seattle group reported
early administration of tocilizumab with and without
dexamethasone after treatment with a 4-
1BB second-
generation CAR T cell product with encouraging data
of a modest decrease in severe CRS.99 A similar clinical
trial at Children’s Hospital of Philadelphia prospectively
tested a preemptive approach in pediatric ALL patients
with high disease burden (>40% marrow blasts), giving
tocilizumab at the time of fever. This preemptive trial met
the endpoint for grade 4 CRS reduction (by one-third) in
these high-risk patients.100
Other cytokine‐directed therapies, such as siltuximab, a chimeric anti‐IL‐6 mAb, have occasionally been
used in the management of CRS.24 85 Based on preclinical models and known cytokine profiles, anti-IL-1 therapies, such as anakinra, have been proposed for CRS
treatment, but data are lacking regarding their efficacies in humans.9 83 Reports have emerged of patients
presenting with atypical, tocilizumab-
refractory CRS,
characterized by early increases in GM-CSF and IL-2,101
highlighting a need for alternate approaches. In cases
of CRS that do not respond to 2 to 3 doses of tocilizumab, benefit with additional doses is unclear. Additionally, a retrospective analysis of 100 patients with
RR large B cell lymphoma treated with axicabtagene
ciloleucel found a trend for shorter progression-free
survival (PFS) among patients receiving corticosteroids
for a prolonged time.102
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Panel recommendations
For elderly patients or patients with extensive comorbidities, tocilizumab should be considered earlier in
the course of CRS.
►► For adults who develop ASTCT grade 2 CRS, tocilizumab may be considered (LE: 398).
►► For pediatric patients, tocilizumab should be administered at ASTCT grade 3 CRS (LE: 37).
►► For pediatric patients who develop prolonged ASTCT
grade 2 CRS or intolerance to fever, tocilizumab may
be administered (LE: 47).
►► In both adults and children, if CRS does not improve
after 1 dose of tocilizumab, then steroids should be
administered with a second dose of tocilizumab (LE:
321 31 52).
►► If CRS does not improve after 2 doses of tocilizumab
(and steroids), third-
line agents, including anakinra, siltuximab, and high-dose methylprednisolone,
should be considered (LE: 49 96).
►► If CRS does not improve after tocilizumab and steroids, infections should be considered again in the
differential diagnosis and managed appropriately.
►► If steroids are used in the management of CRS, a
rapid taper should be used once symptoms begin to
improve.
►►

HLH/MAS-LIKE TOXICITY
The spectrum of clinical features and laboratory abnormalities seen in CRS overlap substantially with HLH and
MAS.50 In these cases, the MAS features usually respond
to CRS therapy. In addition, reports have emerged of
patients developing fulminant inflammatory coagulopathies with clinical features similar to grade 3 or 4 CRS
characterized by high fevers, elevated ferritin levels,
increased liver enzymes, and persistent pancytopenias
later, even weeks, after CAR T cell infusion.103 Because
of the atypical timing of onset and observations that
these late CRS events may not respond to tocilizumab, in
these later events MAS may predominate.50 85 HLH/MAS
is a potentially life-
threatening dysfunctional immune
response characterized by hyperactive macrophages and
lymphocytes, proinflammatory cytokine hypersecretion,
tissue infiltration, hemophagocytosis, and organ damage.
Primary HLH is an autosomal recessive genetic disease
with an incidence of roughly 1 in 100,000 live births, and
a median survival of less than 2 months without treatment. The more common, though still rare, presentation
is secondary, or reactive, HLH or MAS, which may be
triggered by infections (especially EBV, CMV, and HIV),
autoimmune diseases, and cancers. HLH is believed to
occur in as many as 1% of patients with hematological
malignancies, and mortality rates associated with HLH
secondary to cancer approach 80%.103
Most patients with moderate to severe CRS have laboratory results that meet the classic criteria for HLH/MAS,
including elevated serum levels of IFNγ, IL-10, sIL-2Rα,
IL-6, IL-8, and GM-CSF,28 50 85 but may or may not have
hepatosplenomegaly, lymphadenopathy, or overt evidence
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of hemophagocytosis. CRS and HLH/MAS substantially
overlap clinically; therefore, using clinical management
guidelines for CRS initially when HLH/MAS is suspected
is warranted. The management of late-onset severe CRS
may be challenging, especially if tocilizumab does not
resolve symptoms. Treatment of bona fide HLH/MAS
typically involves cytotoxic chemotherapy, such as etoposide.104 This approach is not recommended for patients
undergoing CAR T cell therapy, due to etoposide’s documented toxicity to T lymphocytes105 106 and lack of data
in this setting.103 Anecdotal reports have surfaced of
successful resolution of symptoms after anakinra administration107; however, no prospective studies document the
efficacy of any one specific intervention.
Panel recommendations
CRS and HLH/MAS substantially overlap.
►► However, late-
onset, tocilizumab-
refractory HLH/
MAS-like symptoms may represent a distinct and separate pathology than conventional CRS (LE: 4108).
►► Delayed coagulopathy may possibly be one hallmark
of delayed onset HLH/MAS-
like toxicity, typically
hypofibrinogenemia disproportionately worse than
changes in PT/PTT, which requires close follow-up
and replacement with cryoprecipitate (LE:4103 108).
►► Etoposide should only be administered to patients
experiencing late-onset, tocilizumab-refractory HLH/
MAS-like symptoms after CAR T cell therapy as a last
resort (LE: 4103).
►► For treatment of late-onset, HLH/MAS-like pathology,
which may be tocilzumab-refractory, third-line CRS
agents such as anakinra and steroids may be considered (LE: 483 107).
►►

IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY
SYNDROME
Transient neurological complications have been reported
in nearly every trial targeting T cells to CD19, including
studies involving CAR T cells and BiTEs.76 The likelihood of neurological toxicity may vary depending on the
product and disease state. For example, the reported incidence of neurological toxicities is 87% for axicabtagene
ciloleucel.1 For tisagenlecleucel, neurological toxicity was
reported in 72% of patients with RR ALL and 58% of
patients with RR DLBCL.2 Although fewer patients have
been treated with the BCMA-targeting CAR T product
bb2121, the rate of neurotoxicity in a phase I trial was
42%, with only one patient experiencing toxicity ≥ grade
3.16 The frequency of neurological events has been
rare in trials for the treatment of solid tumors, such as
in a phase I/II clinical study of a HER2-specific CAR T
therapy, where no neurotoxicity was reported among all
19 patients.109 However, efficacy of IEC in solid tumors
has been more limited, and it is possible that the incidence of ICANS may increase with the development of
more efficacious products.
Although the ASTCT consensus guidelines include
elevated intracranial pressure and edema as domains
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for ICANS grading (see and tables 3 and 4), it is unclear
whether cerebral edema arises from a distinct pathophysiology.75 Reports have emerged of lethal cerebral edema
after treatment with CD19-directed CAR T cells in six
patients across two different studies,11 36 another fatal case
in the standard of care setting,110 as well as one case of
reversible cerebral edema in a patient receiving BCMA-
targeting CAR T cells.111
The pathophysiology behind ICANS is an active area
of investigation. Current hypotheses hold that systemic
inflammation and cytokine production after CAR T cell
infusion drives a cascade of endothelial cell activation
and blood–brain barrier disruption, leading to elevated
cytokine levels in the cerebral spinal fluid (CSF), and, in
severe cases, hemorrhage and cerebral edema.27 48 51 56
Across multiple studies, patients who developed severe
ICANS exhibited higher serum levels of proinflammatory
cytokines, such as IL-2 and IL-15 as well as cytokines known
to activate endothelial cells, including IL-6, IFN-γ, and
TNF-α.9 23 24 27 48 51 56 Importantly, IL-6 receptor blockade
is generally considered not effective for resolving neurological symptoms.22 75 95
Severe ICANS is often associated with a consumptive
coagulopathy and patients display elevated serum levels
of laboratory markers of endothelial dysregulation
including von Willebrand factor (vWF), which is released
on endothelial cell activation, and angiopoietin 2 (ANG2),
which is a TIE2 antagonist that shifts the balance of endothelial cells in the blood–brain barrier away from quiescence.48 56 57 The elevated levels of cytokines, including
IL-6, seen in the CSF of patients with severe ICANS likely
arise due to both blood–brain barrier permeability and
local production by activated microglia, astrocytes, and
macrophages, and the relative contribution of each cell
type remains unclear.27 48 51 52 56 Trafficking of T cells into
the CNS may play some role in the neuropathology, as
indicated by the detection of CAR T cells in CSF from
patients with neurotoxicity in the absence of malignant
CNS disease. Yet CAR T cells have also been detected in
CSF of patients with no detectable neurological pathology,
demonstrating that infiltration alone is not sufficient to
cause toxicity.7 9 112 113
Laboratory parameters, baseline tests for ICANS
Several of the cytokine profiles and serum markers associated with ICANS overlap with CRS. During the ZUMA-1
study, severe neurotoxicity was associated with elevated
levels of IL-1Rα, IL-2Rα, IL-6, IL-8, IL-10, IL-15, IFN-γ,
CCL-2, granzyme B, GM-CSF, and ferritin.114 Similarly,
elevated levels of IL-1α, IL-2, IL-3, IL-5, IL-6, IL-10,
IL-15, IFN-γ, G-CSF, GM-CSF, and MCP1 were observed
in the 33 of 53 adult patients with RR B-ALL who developed neurotoxicity during phase I trials of 19-28z CAR T
cells.51 A study encompassing 133 patients with relapsed
B cell malignancies reported elevated CRP, ferritin, IL-6,
IL-8, MCP1, IFN-γ, and TNF-α in the 53 patients who
developed ICANS.57 Markers of diffuse intravascular
coagulation have also been correlated with high-grade
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neurotoxicity, with two studies reporting elevated vWF
and high ANG2:ANG1 ratios in patients with severe
ICANS.51 56
Prior to infusion, patients should be evaluated for
baseline neurological and mental status. The ASTCT
consensus grading system for ICANS (see tables 2 and 3)
deploys a 10-point scoring metric called the ICE tool75 for
ICANS-associated encephalopathy in adults, which builds
and simplifies the assessment items developed in the
CARTOX criteria.28 Points are assigned for orientation
to year, month, city, and hospital, ability to name three
objects, ability to follow simple commands, ability to write
a standard sentence, and ability to count backwards from
100 by 10. For pediatric patients, the CAPD is used.75
Panel recommendations
To monitor neurological function in patients treated
with CAR T cell therapy, the ASTCT ICANS grading
system and criteria should be used.
►► For patients who develop ICANS, the work-up should
include CRP, CBC, CMP, fibrinogen, prothrombin
time test, and international normalized ratio (PT/
INR). A head CT should also be considered. In addition, careful consideration of electroencephalogram
(EEG) and neuroimaging by brain MRI may be necessary (LE: 451).
►►

Increased risk factors upon assessment
Across studies the most consistent factors associated with the development of neurotoxicity have
been disease burden and peak CAR T cell expansion.51 56 114 Classification tree modeling from the
Fred Hutchinson Cancer Research Center study
demonstrated that patients with fever of ≥38.9°C and
serum IL-6 of ≥16 pg/mL and MCP-1 of ≥1343.5 pg/
mL in the first 36 hours after CAR T cell infusion
were at high risk of subsequent grade ≥4 neurotoxicity (sensitivity 100%; specificity 94%).56 Other risk
factors include extramedullary disease,51 younger
age, pre-e xisting neurological comorbidities, higher
total CAR T cell doses, and cytopenias. 56 High-grade
CRS is associated with a greater risk of ICANS.23
Although real-
t ime serum cytokine monitoring is
typically unavailable outside a few academic centers,
several biomarkers have been significantly associated with neurological adverse events, including IL-6,
IL-10, IL-15, IL-2 Rα, and granzyme B.24 Fludarabine-
containing conditioning regimens have been raised
as a concern, 56 and initially fludarabine was thought
to have increased the risk of lethal cerebral edema
during the ROCKET trial of JCAR015. 115 This was not
borne out, because additional deaths occurred with
a modified lymphodepletion regimen. Because the
neurological symptoms and timing of onset associated
with fludarabine are distinct from those seen with
CD19 CAR T neurotoxicity, the agent has now come
to be broadly recognized as not a primary driver for
ICANS.97 More likely, the addition of fludarabine may
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have contributed indirectly to greater baseline lymphopenia and consequent further expansion of CAR T
cells mediating toxicity. Therefore, it should be recognized that the interaction between an individual cell
product and the lymphodepleting regimen may be a
determinant of toxicities.
The incidence of ICANS seems to be highest for
CD19-targeting CAR T cell therapies, potentially due
to the robust T cell expansion seen with CD19 CAR
T cell products. 7 19 22 27 31 35 48 51 52 56 79 Neurological
toxicity has been reported in studies of CAR T cells
directed against CD22 and BCMA, but initial data
suggest that ICANS may occur at lower rates than for
CD19 CAR T cells, although the number of published
studies is too small to make any definitive conclusions. 16 116 No studies have directly assessed differences in risk for ICANS between CAR T cells with
CD28 and 4-1BB costimulatory motifs, and comparisons are complicated by the fact that these products
were evaluated in trials with different grading systems,
patient populations, and disease states. In general,
neurological events were reported more frequently
for axicabtagene ciloleucel 1 than tisagenlecleucel 2
and the robust early expansion of CD28-c ostimulated
CD19 CAR T cells could potentially set the stage for
CRS and ICANS, but neurotoxicity has been reported
in trials of products containing both costimulatory
domains.
Panel recommendations
►► Patients with high disease burden prior to infusion
or treated with CD28-containing CAR T cell products
may be at increased risk for developing neurotoxicity
after CAR T cell therapy (LE: 360 117).
►► Patients with grade 3–4 CRS are at higher risk of
ICANS (LE: 4118).
►► Product-specific and patient-specific risk assessments
should guide treatment decisions for ICANS.
►► Patients with evidence of recent or active intracranial
hemorrhage should not undergo CAR T cell therapy
(LE: 4119).
Clinical signs and symptoms for identification of ICANS
Common clinical manifestations of ICANS include confusion or delirium, expressive aphasia, weakness, tremor,
headache, seizures, and altered level of consciousness.95
Headache alone is not considered a useful diagnostic
symptom for ICANS, as it is very common with CRS and
frequently co-occurs with fever.75 Seizures have occurred
with variable frequency, with some centers observing non-
convulsive status epilepticus in roughly 10% of patients
treated with CAR T and one study reporting generalized
tonic–clonic seizures in roughly 30% of patients.48 51 56
Aphasia, in particular anomia, and word-finding defects
may be an important early warning sign, as one study
of 53 patients with RR ALL found that 85% of subjects
who displayed impaired naming of objects, stuttering, or
perseverative speech after treatment with an anti-CD19
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CAR T went on to develop severe ICANS.51 Handwriting
changes have also been reported as the first sign to appear
prior to the onset of high-grade ICANS.23 28 116 Although
CRS and ICANS are considered separate pathologies,
fever precedes the onset of neurological symptoms in a
majority of patients.23 24 51 56
Cerebral edema may appear as areas of low density on
unenhanced CT images and as increased T2 and FLAIR
signal changes on MRI. Visible edema on neuroimaging
is classified as grade 3 or grade 4 ICANS by the ASTCT
consensus system, depending on whether it is local or
diffuse.75 In the majority of cases, however, patients with
ICANS frequently present with unremarkable MRI and
CT scans.51 79 Findings on EEG may reveal non-convulsive
status epilepticus in CAR T-treated patients, with diffuse
slowing and frontal intermittent rhythmic delta activity
(FIRDA).48 However, FIRDA and generalized background
slowing on EEG are both non-specific signs of diffuse
cerebral dysfunction also seen in metabolic encephalopathy, infections, centrally acting medications, or
neurodegeneration.120
Panel recommendations
As per the ASTCT consensus grading system, mental
status changes define the onset of ICANS after CAR T
cell therapy.
►► Brain CT or MRI may be used to evaluate cerebral
edema in cases of grade 3 ICANS in adults, but the
initiation of ICANS management should not be
delayed for confirmation of neurological symptoms
with imaging findings (LE: 451).
►►

Timing of ICANS
Across trials, the median time-to-onset of neurological
events has been reported as 4–5 days after infusion and
resolution has typically been seen within 3–8 weeks.23 24 56 121
Neurological toxicity may occur earlier in patients treated
with CD28 costimulated CAR T cells than for those
receiving products with a 4-1BB domain. For axicabtagene ciloleucel, the median time to onset is 4 days after
infusion, and for tisagenlecleucel, the median time to first
event is 6 days.1 2 ICANS has been observed concurrently
with CRS, shortly after CRS symptoms subside, as well as
a delayed-onset form occurring up to 1 month after CAR
T cell infusion.9 28 114 The duration of neurological toxicities may vary depending on the product and disease state.
For axicabtagene ciloleucel, the median duration was 17
days, and for tisagenlecleucel, the median duration was
6 days for patients with RR ALL and 14 days for patients
with RR DLBCL. In most patients ICANS resolved within
3 weeks, although prolonged encephalopathy lasting up
to 173 days was noted.1 2 Long-term follow-up studies of
patients treated with CAR T cells are ongoing, and late-
onset neurological events have been reported. Among 86
patients treated with CD19 CAR T cells in a phase I/II
trial, 9 (10%) were found to have 11 new neurological
findings at a median of 28.1 months (range 12.1–62.6)
after infusion, including three cerebrovascular accident
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events and one transient ischemic attack. Additionally, eight patients (9%) experienced psychiatric events
requiring intervention: four with newly diagnosed mood
disorders and four with exacerbation of previous depression and anxiety.122

Kettering Cancer Center trial, 14 patients developed
seizure despite levetiracetam prophylaxis, but all resolved
with standard management with benzodiazepines and
antiepileptic agents.51

Panel recommendations
►► Product label and product-
specific REMS, or trial
specific guidelines, should inform the duration and
frequency of monitoring for ICANS after infusion.
►► In patients deemed to be at high risk for developing
ICANS, inpatient treatment, earlier imaging, or more
frequent monitoring may be warranted.
►► Patients treated with axicabtagene ciloleucel should
be assessed for ICANS twice daily during the first
week after infusion. The package insert requires at
least once daily, but many experts recommend formal
assessments more frequently (LE: 32).
►► As centers gain more experience administering CAR
T cell therapies, requirements for monitoring may
be modified with the best judgment of the treating
physician.

►►

Management of ICANS
Across several trials, tocilizumab has failed to resolve symptoms of ICANS, despite alleviating severe CRS.23 24 51 56 It
remains to be determined whether targeting IL-6R in
isolation during established CRS is insufficient to prevent
subsequent neurotoxicity or if the lack of efficacy is due to
tocilizumab’s inability to cross the blood–brain barrier.123
Because tocilizumab may not penetrate the CNS and
causes at least a transient rise in serum IL-6, some have
postulated that it may worsen neurotoxicity by increasing
IL-6 antibody
CSF IL-6 levels.56 123 Siltuximab, an anti-
that may prevent high IL-6 concentration in the CSF by
removing it from circulation in the serum, and the IL-1
antagonist, anakinra, have both been proposed as potential alternatives, but data are lacking on their safety and
efficacy.
Corticosteroids have been successfully used for the
management of ICANS. The axicabtagene ciloleucel
package insert advises 10 mg IV dexamethasone every
6 hours for neurological toxicity of ≤grade 3 and 1000 mg
IV methylprednisone daily for 3 days with grade 4
ICANS.1 Although corticosteroids may reduce circulating
CAR T cell counts, evidence is emerging that even longer
courses of steroids (>7 days) do not alter efficacy of cancer
treatment.118 However, a trend towards shorter PFS has
been observed in patients with lymphoma treated with
axicabtagene ciloleucel who received longer and earlier
intervention with steroids.102
Seizure prophylaxis has been implemented in a few
studies, but the ideal dose and duration have not yet
been determined.28 48 51 Levetiracetam has a better drug–
drug interaction profile and lower risk of cardiotoxicity
compared with other antiepileptic agents, can be administered safely to patients with hepatic dysfunction, and
does not affect cytokine levels.28 In the Memorial Sloan
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Panel recommendations
Based on the expected neurotoxicities seen with
different CAR T cell therapies, the management of
ICANS should be risk-
adjusted based on product-
specific and patient-specific characteristics.
►► Patients with CNS involvement of their disease may
need earlier intervention for ICANS.
►► Patients with history of inflammatory neurological
conditions or current CNS disease involvement should
be referred for additional neurological consultation
prior to initiating CAR T cell therapy.
►► For brain imaging in patients deemed high risk, MRI
is preferred. If a patient is too unstable to transport,
or fast-brain MRI is unavailable for pediatric patients
(thus necessitating sedation), CT imaging may be
used (LE: 479).
►► Because of the possibility that tocilizumab may worsen
neurotoxicity, the management of neurotoxicity may
take precedence over the management of low-grade
CRS (LE: 556 123).
–– For example, in the case of a patient with concomitant grade 1 CRS (fever) and grade 2 ICANS, steroids should be given.
–– This does not apply to higher-grade CRS.
►► If steroids are used in the management of ICANS, at
least 2 doses should be given and a fast taper should
be used once there is improvement (LE: 31 2).
►► For patients with grade 2 ICANS after being treated
with 4-1BB CAR T cell products, such as tisagenlecleucel, steroids may be considered. Steroids are
recommended for grade 3 or grade 4 ICANS (LE:
423 117 124).
►► For patients with grade 2 ICANS after being treated
with CD28 costimulated CAR T cell products such
as axicabtagene ciloleucel and brexucabtagen autoleucel, steroids should be used to mitigate the duration and severity of ICANS (LE: 324 125).
►► To manage seizures in patients treated with CAR T cell
therapies, levetiracetam is recommended (LE: 424 30).
►► There is insufficient evidence to recommend prophylactic antiseizure medications to all patients undergoing CAR T cell therapies. However, in patients
deemed to be at high-risk of developing neurotoxicity based on history, disease characteristics, or the
product being administered, prophylactic levetiracetam may be considered (LE: 451).
Cerebral edema
The high-profile termination of the phase II ROCKET
trial (NCT02535364) of the investigational CD19-CAR T
JCAR015 in adults with RR ALL raised concerns about the
danger of fatal cerebral edema in patients undergoing
IEC therapies.115 Fatalities were also reported during
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the safety expansion phase of the ZUMA-1 study,36 in the
standard of care setting,110 as well as the phase I/II trial
of JCAR014, a defined composition CD4+/CD8+ CAR T
cell product for the treatment of RR ALL, CLL and NHL
(NCT01865617).11 Initially, the use of fludarabine as a
lymphodepleting agent was suspected as the etiological
agent for cerebral edema, leading to a modified conditioning regimen in the ROCKET trial. However, subsequent fatalities, in addition to the distinct manifestation
and timing of symptoms for adoptive T cell transfer-
associated neurotoxicity, led to the conclusion that fludarabine may not be the primary cause for cerebral edema
and that the agent may continue to be safely used for
lymphodepletion.97
All five patients who died in the ROCKET trial experienced rapid, early expansion of the modified CAR-bearing
T cells within a week of being infused. Additionally, high
levels of CD8+ T cells and a concurrent sharp spike in
IL-2 and TNF-α were significantly correlated with fatal
brain swelling.115 Postmortem analyses of patients from
both the ROCKET and ZUMA studies revealed blood–
brain barrier disruptions in patients who succumbed to
cerebral edema subsequent to CAR T treatment.56 119 In
the ZUMA-2 trial, one case of grade 4 cerebral edema
occurred; the patient had a full recovery and was in
complete remission at 24 months of follow-up with no
unresolved neurological sequela.14 Blood–brain barrier
pathology was also reported in a patient who developed
edema as a feature of CRS after CD19-directed CAR T
therapy.126 Disruption of the blood–brain barrier may
allow systemic cytokines including IFN-γ to leak into
the CSF, thus inducing vascular pericyte stress and the
secretion of endothelial cell-activating cytokines. Therefore, there is speculation that patients with evidence
of endothelial cell activation before lymphodepletion
may be at increased risk of ICANS.56 A report has also
surfaced of severe neurotoxicity consistent with posterior
reversible encephalopathy syndrome in a phase I trial
of CART-BCMA for multiple myeloma (NCT02546167),
which resolved after high-dose methylprednisolone and
cyclophosphamide.111
Panel recommendation
If cerebral edema is suspected based on clinical
signs and symptoms, patients should be immediately
referred to intensive care where rapid imaging and
management of intracranial hypertension should be
performed (LE: 4119).

►►

CYTOPENIAS
Lymphodepletion has become an important component
of IEC therapies, associated with improved responses
across trials, and regimens containing both fludarabine
and cyclophosphamide are linked to better clinical
outcomes.4 23 24 36 38 96 127 Hematological recovery after
lymphodepletion and CAR T cell infusion varies across
CAR T cell products, however, and hematological recovery
for CD19-directed CAR T cell therapies may be more
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delayed. Grade 3 or 4 cytopenias persisting more than 30
days after CAR T cell infusion were observed in roughly
30% of patients receiving both axicabtagene ciloleucel
and tisagenlecleucel.24 36 38 Additionally, cytopenias were
among the most common grade 3 or higher adverse events
reported in the JULIET, ZUMA-1, ZUMA-2, and ELIANA
trials.14 23 24 38 121 For newer products, such as BCMA-
targeting bb2121, cytopenias were the most common
events of grade 3 or higher, including neutropenia (in
85% of the patients), leukopenia (in 58%), anemia (in
45%), and thrombocytopenia (in 45%).16 Short-lived
cytopenias are to be expected after the standard lymphodepletion regimen that is recommended with approved
CAR T products,1 2 but prolonged cytopenias, even in the
absence of lymphodepletion, may occur more frequently
after CD19 CAR T cell therapy.5 7 8 Cytopenias may also
be a hallmark of myelodysplastic syndromes,128 which is
important to consider in the differential diagnosis. Risk
factors for prolonged cytopenias observed in the ELIANA
trial included prior HSCT, high disease burden, and high-
grade CRS. Notably, no persistent cytopenias of grade 3
or higher were reported in trials of EGFRvIII- and HER2-
directed CAR T cell therapies for the treatment of glioblastoma.129 130
Timing of cytopenias
In roughly one-
third of patients treated with CD19-
directed CAR T cells, cytopenias persisting for >1 month
have been reported.7 23 57 58 One report has described
prolonged cytopenias persisting for 15.2–21.7 months
after CD19 CAR T cell treatment122 and another reported
that 10% of adult lymphoma patients that remain in
remission after axicabtagene ciloleucel may continue
to experience grade 3–4 neutropenia 1 year after the
therapy.131 Of note, the latter study of 85 patients in the
standard of care setting noted that while CD8+ counts
rapidly recovered, CD4+ T cells decreased from baseline
and were persistently low with a median CD4 count of
155 cells/µL for those remaining in remission 1 year after
axicabtagene ciloluecel.131 For other therapies, hematological recovery following lymphodepletion generally occurs more rapidly. For example, 97% of patients
receiving BCMA-targeting bb2121 CAR T cells who experienced grade 3 or higher cytopenias recovered to an
absolute neutrophil count (ANC) of at least 1000 cells/µL
within 1 month. In that trial, the median time from infusion to recovery of an ANC of at least 1000 cells/µL was
1.3 weeks (95% CI 1.0 to 1.4) and recovery to a platelet
count of at least 50,000/µL occurred in a median of 2.0
weeks (95% CI 1.4 to 8.4).16 132
One study identified a biphasic pattern to cytopenias
following CD19 CAR T cell therapy. In the trial, 27 of 29
responding patients experienced cytopenias later than
21 days postinfusion. Of the 22 patients who experienced late neutropenia, 15 showed two distinct nadirs in
absolute neutrophil counts with one trough shortly after
lymphodepletion and a second occurring more than 40
days after infusion. A similar biphasic pattern occurred
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in the 22 patients who experienced grade 3 thrombocytopenia, with 10 patients displaying an initial recovery of
platelet counts before a second nadir between 20 and 40
days after infusion.133 In another analysis, baseline platelet
counts of <75,000 and the early onset of CRS on day 0 or
day +1 following infusion were associated with a higher
likelihood of development of severe and prolonged cytopenias, which in some cases required therapy as for graft
failure following allo-HSCT.132
Panel recommendations
For cytopenias occurring within the first 28 days after
IEC infusion, a bone marrow biopsy may not be indicated—complete blood counts with differential may
be adequate for follow-up (LE: 4133 134).
►► Clinically stable, afebrile pediatric patients may be
discharged from the hospital before blood counts
recover, though antimicrobial and antifungal prophylaxis should be considered.
►► For cytopenias persisting >28 days after IEC infusion,
bone marrow biopsy and bone marrow aspiration
should be performed in addition to the standard
work-up to assess response and cellularity, including
assessment of viral pathogens (LE: 4133 134).
►►

Increased risk factors for cytopenias upon assessment
A correlation between late (more than 21 days after infusion) thrombocytopenia, neutropenia and anemia was
observed (p=0.018 for thrombocytopenia and neutropenia,
p<0.0001 for thrombocytopenia and anemia, and p=0.05
for anemia and neutropenia) in a phase Ib/II trial of
CD19 CAR T cells for 38 children and adults with RR B cell
cancers. In that study, prior HSCT (p=0.0015, 0.0083, and
0.02 for anemia, thrombocytopenia, and neutropenia) and
higher CRS grade (p=0.003, 0.018, and 0.04 for late anemia,
thrombocytopenia, and neutropenia) predicted the development of cytopenias.133 Grade 3 or 4 CRS was also linked
to delayed hematological recovery in 133 patients with RR
B-
ALL, CLL, or NHL who underwent lymphodepletion
chemotherapy followed by infusion of CD19 CAR T cells.
Examination of bone marrow biopsies from patients with
grade 4 CRS showed no evidence of increased hemophagocytosis that might contribute to the delayed recovery;
however, pretreatment bone marrow disease burden and
a high number of prior therapies were associated with
prolonged cytopenias in the study population.57
Panel recommendations
Patients who develop high-
grade CRS may be at
increased risk for developing prolonged neutropenia
(LE: 4122).
►► Adults and children treated with CAR T cells outpatient should be hospitalized if they develop active
infections or febrile neutropenia or per institutional
guidelines. Evaluation for immune-mediated cytopenias could be considered, depending on the clinical
circumstance.
►►
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Management of cytopenias
The package insert for tisagenlecleucel recommends
against using myeloid growth factors, particularly GM-CSF
during the first 3 weeks after cell infusion or until CRS
has resolved because GM-CSF may theoretically aggravate
CRS.1 6 Some centers recommend filgrastim (recombinant
G-CSF) for all patients with ANCs lower than 500/µL.28 31
Without growth factor support, thrombocytopenia and
anemia may resolve more slowly than neutropenia. One
retrospective analysis of 32 RR DLBCL patients treated
with CD19 CAR T cells observed median times to neutrophil, platelet, and hemoglobin recoveries of 11 days
(range 5–218 days), 59.5 days (range 4–241 days), and 76
days (range 0–218 days), respectively. Fifteen patients in
the cohort were treated with filgrastim.134
Panel recommendations
For neutropenia during the first 28 days after CAR
T cell infusion, G-CSF has been used. To avoid interaction with the peak CRS risk and CART expansion
period, consider holding growth factors until day 14
from infusion of CAR T cells or once CRS has resolved
(LE: 4133).
►► For persistent neutropenia (ANC<500 cells/µL) after
day 28 following CAR T cell infusion, growth factors
should be considered (LE: 4134).
►► If growth factors are administered, GM-
CSF is not
recommended until the risk period for CRS is over
(usually 2 weeks) (LE: 583).
►►

CARDIOLOGY
Cardiac toxicities are reported at rates of 29%–39% in
patients receiving tisgenlecleucel, axicabtagene ciloleucel, and brexucabtagene autoleucel.1–3 However, the
interpretation of these data is challenging because definitions of cardiotoxicity may vary. A common definition
of cardiac toxicity includes symptoms of heart failure
and/or a decline of left ventricular ejection fraction
(LVEF): symptomatic fall in LVEF from ≥5 to <55% or
an asymptomatic reduction of LVEF from ≥10 to <55%.
However, additional definitions include an increase in
serum troponin, a greater decline in LVEF, and a >15%
reduction in global longitudinal strain.135 The CTCAE
grades cardiotoxicity based on symptomology, imaging
abnormalities, and biomarker measurements, including
troponins.136
Common cardiovascular and cardiac toxicities reported
with CAR T cell therapies have included hypotension, new
heart failure, worsening of pre-existing heart failure, and
new arrhythmias (atrial fibrillation/flutter are common).
Other cardiac events that have been observed are the
following: non-
sustained ventricular tachycardia (VT),
prolonged corrected QT interval (QTc) with and without
QTc prolonging medications or electrolyte abnormalities, other wide and narrow complex tachycardias, pericarditis, and myocarditis.42 While cardiac toxicities have
generally resolved there have been a small number of
cases that have led to mortality. A retrospective analysis of
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98 children with RR ALL treated at a single center with
4-1BB-costimulated anti-CD19 CAR T cells observed hypotension requiring inotropic support in 24 patients with
a mean onset 4.6 days after CAR T cell infusion (range
1–9), including six patients receiving milrinone. Worsened systolic function occurred in 10 patients.137 In a
retrospective study of 137 adult patients treated with CAR
T cells, cardiac injury (defined as an increase in serum
troponin) was documented in at least 21% of patients
and the cardiovascular event rate was 12%.91 An elevated
serum troponin was noted prior to the occurrence of a
cardiac event after CAR T cell infusion and was exclusively
noted in those with CRS. No trials have directly addressed
cardiac risk factors in the context of CAR T cell therapy;
however, an observational study aiming to prospectively define the rate of occurrence, natural history, and
progression of cardiac dysfunction after CD19 CAR T cell
therapy in adults and to identify the patients at high risk
of developing cardiovascular events is ongoing at the time
of publication (NCT04026737).
Baseline evaluation for cardiotoxicity
A baseline measurement of cardiac function is important.
Echocardiography is the principal technique for evaluating cardiac toxicity in patients with cancer and three-
dimensional echocardiography-derived LVEF correlates
excellently with MRI findings, while two-
dimensional
speckle tracking echocardiography-
derived strain can
detect changes in myocardial mechanics before changes
in LVEF occur.138–140 Historically, equilibrium radionuclide angiography/MUGA has been a preferred method
for serial assessment of LVEF in adult patients undergoing cardiotoxic chemotherapy due to high reproducibility, low interobserver and intraobserver variability, and
extensive validation literature. Routine use of MUGA has
markedly diminished in recent years because of the relative ease of use and low cost of echocardiogram.141 Additionally, MUGA exposes patients to radiation through the
use of 99m-technetium labeled red blood cells, making
echocardiogram the preferred modality for monitoring
adult and pediatric patients.142
Several cardiac biomarkers have established utility
in the detection of cardiac injury with cancer therapies
and have also been validated for their prognostic value
both in symptomatic and asymptomatic patients free
of cancer. For example, the N-terminal pro-brain natriuretic peptide (NT-proBNP) investigation of dyspnea in
the emergency department study of 600 patients who
presented in the emergency department with dyspnea
found that increased serum NT-proBNP was the strongest independent predictor of a final diagnosis of acute
congestive heart failure (OR 44; 95% CI 21.0 to 91.0,
p<0.0001) and NT-proBNP testing alone was superior to
clinical judgment alone (p=0.006).143 Cardiac troponins
are the gold standard biomarker for myocardial injury,
and high-sensitivity assays allow for the improved detection of heart tissue damage even in the absence of
overt signs and symptoms.144 145 However, an elevated
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troponin may occur independently of acute myocardial
infarction, and myriad etiologies have been linked to
troponin release, including pulmonary embolism, heart
failure, myocarditis, end-stage renal disease, tachycardia,
strenuous exercise, septic shock, and treatment with
cardiotoxic chemotherapy such as doxorubicin and with
immune checkpoint inhibitor therapy.140 146–149
Panel recommendations
In adults, baseline cardiac testing prior to CAR T cell
therapy should include TTE, a serum troponin, and
NT-proBNP/BNP (LE: 491 137).
►► In adults, troponin and LVEF should be monitored
in patients who develop CRS of ASTCT grade 2 or
higher (LE: 491).
►► In children, left ventricular shortening fraction
should be monitored at baseline and in patients with
ASTCT grade 4 CRS.
►►

Increased risk factors for cardiotoxicity upon assessment
Many patients treated with CAR T cells have undergone several prior lines of therapy, including chemotherapy with cardiotoxic agents. According to some
estimates, 57%–70% of elderly lymphoma patients and
50%–60% of childhood cancer survivors are treated
with an anthracycline-
containing regimen.149 Anthracyclines, especially doxorubicin, can cause irreversible,
dose-dependent cardiac injury, and the risk for future
complications increases with cumulative doses. The onset
of a decreased LVEF may occur while a patient is on
treatment with anthracyclines or several years later.149–151
Serial serum troponin measurement in 78 patients with
hematological malignancies undergoing 142 treatment
cycles, including various anthracyclines, revealed delayed
subclinical myocardial damage even after minor anthracycline exposure, with peak levels observed on median
day +21.5 (range day +6 to day +35) after initiation of
anthracycline therapy. Follow-up echocardiography in 28
patients showed a greater decrease in LVEF in troponin-
positive patients compared with the troponin-
negative
group (10% vs 2%; p=0.017).124
Elevated troponins and BNP/NT-proBNP have been
associated with increased all-
cause mortality and have
been shown to predict heart failure in patients with cancer
undergoing chemotherapy.152 153 Increased troponin
levels correlated with decreased LVEF in patients with
acute myeloid leukemia (AML) undergoing induction
chemotherapy with anthracycline-containing regimens.154
Among patients undergoing CAR T cell therapy, elevated
serum troponins have been observed prior to cardiac
events and post-CAR T cell infusion.53
In addition to prior therapies, the risk factors for
cardiac toxicity with treatment are likely similar to those
for the development of severe CRS, specifically, disease
burden and peak CAR T cell expansion.27 28 137 155 156 The
pathophysiology responsible for cardiac toxicity in the
context of CAR T cell therapy has not been extensively
studied; however, the inflammatory cytokine profile seen
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with CRS, specifically elevated levels of IL-6, has also been
implicated in causing myocardial dysfunction in cases of
septic shock.157 One of the hallmarks of CRS is hypotension,28 29 31 85 90 155 156 which may lead to distributive shock,
myocardial injury, and arrhythmias. Medications that
increase bleeding risk could accelerate the onset of life-
threatening shock.
The underlying cardiovascular substrate, beyond
cardiovascular function, is also likely a risk factor for the
development of cardiac injury and cardiovascular events
with CAR T. Specifically, many adult patients receiving
CAR T cells may be elderly and have underlying cardiovascular risk factors such as hypertension and diabetes
mellitus and may have established cardiovascular diseases
such as heart failure and coronary artery disease. There
are limited data specific to CAR T, but in a single retrospective study of 137 subjects, the rates of these cardiovascular risks were higher in those that subsequently
developed cardiac injury.91
Patients with high preinfusion disease burden are also
at risk of developing TLS,7 8 10 which may cause cardiac
complications secondary to the flood of metabolites and
electrolytes, including uric acid released into circulation.92 In particular, elevated serum uric acid has been
implicated as a risk factor for cardiovascular events,
including acute myocardial infarction, angina, and heart
failure.158–160
Panel recommendations
Patients with an increased burden of cardiovascular
risk factors, with a prior cardiac insult (ie, prior
myocardial infarct and prior coronary revascularization), significant valvular disease, a low ejection fraction or a cardiomyopathy, a history of heart failure
or significant cardiac, arrhythmias, and a history of
cardiac toxicity from prior therapies should receive
an additional cardiac evaluation prior to CAR T cell
therapy. Patients with significant cardiac disease may
not be candidates for CAR T cell therapy, depending
on the balance between disease and treatment-
associated risks (LE: 491 137).
►► Patients with pre-
existing heart failure, arrhythmias,
or other significant cardiac history may warrant
consideration of inpatient CAR T cell therapy.
►► Based on the expected toxicities seen with different
CAR T cell therapies and disease states, the management of cardiac adverse events should be risk-adjusted
based on product-specific and patient-specific characteristics. Patients deemed to be at high cardiac risk at
baseline might need earlier intervention with tocilizumab and/or steroids at the onset of CRS.
►► The measurement of a serum troponin and LVEF
should be considered in patients with any grade CRS
when additional risk stratification is needed (LE:1153).
►►

Management of cardiovascular adverse events
Coagulopathies frequently occur in the context of CRS, and
disseminated intravascular coagulation has been reported
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at rates of more than 2% for the approved CAR T cell products.161 Patients with cancer are at higher risk of thromboembolism, and clots are a leading cause of death in patients
undergoing chemotherapy.162 163 The goal of anticoagulation therapy is generally to prevent clot formation at the
lowest possible dose of anticoagulant medication, and
management in patients with cancer may be challenging
because some agents are long acting, interact with other
drugs and have narrow therapeutic windows. In particular,
warfarin (Coumadin) has a serum half-life of, on average,
roughly 40 hours and the duration of effect is 2–5 days.164 165
Current major guidelines from the European Society for
Medical Oncology, the National Comprehensive Care
Network and International Clinical Practice recommend
low molecular weight heparin over warfarin for thrombosis
prophylaxis in patients with cancer.166–169
The risk for bleeding complications in patients treated
with anticoagulants is considerable. A meta-analysis of 33
studies involving 4374 patient-years of oral anticoagulant
therapy found that the case-fatality rate of major bleeding
was 13.4% (95% CI 9.4% to 17.4%), and the rate of intracranial bleeding was 1.15 per 100 patient-years (95% CI
1.14 to 1.16 per 100 patient-years).170 Multiple studies
have demonstrated that the presence of malignant disease
significantly increases risk of major bleeding after anticoagulation therapy with warfarin.171 172 Antiplatelet blood
thinners such as aspirin also increase bleeding risks. Additionally, aspirin, and other cyclooxygenase (COX) inhibitors, have been demonstrated to suppress T cell activation
by inhibiting T cell receptor signaling to p38 Mitogen-
activated protein (MAP) kinase,173 174 though no large
controlled trials have assessed whether COX-inhibition
negatively affects the efficacy of CAR T cell therapy.
Panel recommendations
Evidence of cardiac toxicity, elevated troponin,
decrease in LVEF or significant arrhythmias, should
prompt consideration of earlier intervention with
IL-6 blockade and/or steroids or escalation of current
treatment.
►► Malignant arrhythmias or evidence of severe LV
dysfunction is an indication of severe end organ
damage and requires escalation of intervention.
►► The medications that may be continued during CAR
T cell therapy include beta blockers, angiotensin
II receptor blockers, calcium channel blockers,
and ACE inhibitors. If feasible, these medications
should be changed from long-acting to short-acting
formulations.
►► The medications that should be discontinued prior to
CAR T cell therapy include antiplatelet agents such
as aspirin and clopidogrel. In patients who recently
underwent a coronary revascularization, management
decisions regarding the cessation of antiplatelet agents
should be made in conjunction with the primary
cardiology team, and risk–benefit of proceeding with
CAR T cell therapy should be considered.
►►
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►►

►►

►►

►►

Before proceeding with CAR T cell therapy, patients
on therapeutic anticoagulants should be switched
from long-acting to short-acting formulations, wherever possible. Long-acting anticoagulants can significantly potentiate bleeding risk during CRS.
If platelet counts drop below 100,000/µL in patients
undergoing CAR T cell therapy, dual-acting anticoagulants should be discontinued.
If platelet counts drop below 50,000/µL in patients
undergoing CAR T cell therapy, all anticoagulants
should be discontinued unless a patient has a recent
thrombosis.
If platelet counts drop below 50,000/µL in patients
undergoing CAR T cell therapy and the patient has a
recent thrombosis, anticoagulants may be continued,
but the dose should be reduced or platelet transfusions should be administered.

ON-TARGET TOXICITIES: HYPOGAMMAGLOBULINEMIA
The approved CAR T cell products, tisagenlecleucel,
axicabtagene ciloleucel, and brexucabtagene autoleucel, all
target CD19, which is expressed in normal and neoplastic
B cells as well as follicular dendritic cells.175 Almost all
patients who respond to CD19 CAR T cell therapy develop
B cell aplasia after infusion.5 9 31 55 In a phase I/IIa study of
75 children and young adults with RR B-ALL treated with
tisagenleceucel, the rate of event-free survival at 6 months
was 73% (95% CI 60% to 82%), and the probability of
maintenance of B cell aplasia at 6 months after infusion was
83% (95% CI 69% to 91%).23 All patients who responded
to treatment in the ELIANA trial had B cell aplasia, and
the probability of functional CAR T cell persistence and
continued B cell aplasia at 6 months after infusion was
83%.23 A study of humoral immunity in 16 adults and children who responded to tisagenlecleucel reported B cell
aplasia persisting for a mean of 571 days following CAR T
cell therapy.54 CD19+ B cells can recover, however. In the
phase I study of CD19 CAR T cells with a CD28 costimulatory domain in children and young adults with RR leukemia
in the pediatric oncology branch, B cells became detectable
by 60 days in all responding patients.113 In the ZUMA-1 trial
of adults with large B cell lymphomas treated with axicabtagene ciloleucel, 6 (17%) of 35 assessable patients with
ongoing responses had detectable B cells in their blood by
3 months after infusion; 20 (61%) of 33 assessable patients
had detectable B cells at 9 months; and 24 (75%) of 32
assessable patients had detectable B cells at 24 months.36 In
ZUMA-2, grade 1 or 2 hypogammaglobulinemia occurred
in 12 (15%) subjects, and grade ≥3 was observed in one
subject.14 In 16 adults with DLBCL who achieved CR
after being treated with tisagenlecleucel, polyclonal B cell
recovery was sustained in 8 (50%), and the median time to
onset of sustained recovery was 6.7 months.121
Increased risk factors for hypogammaglobulinemia upon
assessment
Hypogammaglobulinemia has been reported across trials,
although the rates have varied, likely due to inconsistent
18

definitions, follow-
up times, patient ages and disease
states. Further complicating matters, many patients who
undergo CAR T cell therapy have undergone prior HSCT
without revaccination and are thus beginning treatment
with a limited antibody repertoire. Younger patients may
be more susceptible to hypogammaglobulinemia, as total
serum IgG levels gradually increase at early ages, with
adult levels of IgG1 and IgG3 subtypes seen between ages 5
and 10 years and IgG2 not reaching maximum levels until
adulthood,176 reflecting increasing plasma cell mass. The
direct link between B cell depletion and hypogammaglobulinemia is difficult to establish because long-lived plasma
cells are CD19 negative175 177 178 and therefore should not
be direct targets for elimination by CD19 CAR T cells.
Plasma cells persisting for at least 746 days in the absence
of B cells has been reported in one patient treated with
tisagenlecleucel, and the same study observed stable levels
of pathogen-specific IgG despite prolonged B cell aplasia
and decreasing total serum IgG in two adult patients.54
Panel recommendation
Following CAR T cell therapy, B cell counts and serum
immunoglobulins should be measured monthly (LE:
454).

►►

Management of hypogammaglobulinemia
Immunoglobulin replacement therapy is FDA-approved
for the treatment of primary immunodeficiencies as well
as select few secondary antibody deficiencies, including
hypogammaglobulinemia in CLL.179 180 A number of
off-label uses of immunoglobulin supplementation have
become incorporated into routine clinical practice, with
varying levels of supporting evidence. Although long-
term B cell aplasia and hypogammaglobulinemia can
persist for several years after CAR T cell infusion,55 181 no
controlled studies have demonstrated definitive benefits
for IgG supplementation. In trials where patients did
receive IgG supplementation, no serious infections were
reported after the initiation of replacement therapy.9 10 55
One study of 28 patients with persistent B cell aplasia and
agammaglobulinemia following CD19 CAR T cell therapy,
where patients were transitioned from intravenous to
subcutaneous immunoglobulin replacement at a median
of 11.5 months (range 4–20), found that increasing serum
IgG level was significantly associated with a lower rate of
sinopulmonary infection (p=0.0072).182
All IgG preparations available in the USA are made
from 10,000 to 50,000 units of plasma pooled from 3000
to 10,000 healthy blood donors. Donors are carefully
screened for blood-
borne pathogens, including HIV,
hepatitis A, B, and C viruses, and parvovirus B19, and at
least two distinct viral inactivation steps are used by all
manufacturers. The adverse events associated with IgG
infusions are typically transient, infusion-
related reactions. Intravenous and subcutaneous formulations have
been developed, and typical starting doses are in the
range of 400–800 mg/kg every 3–4 weeks intravenously
or 100–200 mg/kg/week subcutaneously.183 The decision
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to administer immunoglobulin replacement therapy may
be constrained by product availability, as an ongoing
national shortage has limited supplies at most centers at
the time of writing this article.184
Panel recommendations
For adult patients deemed to be at high risk of infections or with recurrent infections and for children
with serum IgG levels less than 400 mg/dL, immunoglobulin supplementation should be considered (LE:
4183).
►► For patients with long-term B cell aplasia (>6 months)
already on IgG replacement, subcutaneous IgG
supplementation can be given at home and may be
considered (LE: 4182).
►►

OTHER TOXICITIES
Primary CAR induction-associated toxicities
Additional toxicities associated with primary IEC induction have been described, including allergic reaction,
sepsis, and TLS. One patient developed anaphylaxis
and cardiac arrest within minutes of completing a
third infusion of T cells that had been transduced
with a CAR derived from a murine antibody to human
mesothelin,185 although this appears to be an isolated
incident.
More commonly, several studies have reported TLS
after CAR T cell treatment, a pathology arising due to
dramatic electrolyte and metabolite imbalances after
widespread release of cancer cell contents into the bloodstream, which can cause kidney damage due to elevated
levels of serum uric acid and LDH.92 To prevent TLS in
patients from undergoing CAR T therapy, prophylactic
allopurinol is sometimes administered prior to infusions.86 186 However, several trials have reported TLS,
despite preinfusion allopurinol. Symptoms typically
resolved after fluid resuscitation and administration of
the recombinant urate oxidase drug rasburicase.7 8 10 186
In an analysis of 328 pediatric ALL patients undergoing
chemotherapy, factors predictive of TLS were male sex
(OR 1.8; p=0.041), age ≥10 years (OR 4.5; p<0.0001),
splenomegaly (OR 3.3; p<0.0001), mediastinal mass
(OR 12.2; p<0.0001), T cell immunophenotype (OR 8.2;
p<0.0001), CNS involvement (OR 2.8; p=0.026), serum
LDH ≥2000 U/L (OR 7.6; p<0.0001), and elevated
white blood cell (WBC) counts (≥20×109/L) (OR 4.7;
p<0.0001).117 In two separate studies of TLS in patients
with AML, predictive risk factors were male sex, LDH
levels above normal values, creatinine>1.4 mg/dL, uric
acid>7.5 mg/dL, and WBC count>25×109/L.187 188
Fatal sepsis has been reported after CAR T cell
therapy. A 69-year-old man with refractory CLL, despite
negative blood cultures at the time of infusion, died of
acute renal failure consistent with sepsis after administration of 19-28z CAR T cells and cyclophosphamide.189
An analysis of infection events in 19 patients during the
first 30 days after CD19 CAR T cell therapy developed
a prediction model based on three cytokines (IL-8,
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IL-1β, and IFN-γ) that could predict life-
threatening
infection with high sensitivity (training 100.0%; validation 100.0%) and specificity (training 97.6%; validation
82.8%). During the study, a characteristic pattern of
‘double peaks’ of IL-6, where serum levels of the cytokine spiked, dropped and then rose again, appeared in
9 of 11 patients with grade 4–5 infections.190
Panel recommendations
TLS risk should be assessed by monitoring disease
burden, and serum potassium, phosphorus, calcium,
uric acid, and creatinine (LE: 3187 188).
►► If patients have significant bone marrow involvement or large amount of extramedullary disease,
increased TLS risk should be a concern (LE: 192).
►► For prophylaxis against TLS prior to CAR T cell
therapy, allopurinol should be administered (LE:
486).
►► In patients with established TLS after CAR T cell
therapy, rasburicase should be considered (LE:
48 10). Testing for G6PD deficiency prior to administration of rasburicase can be considered in patients
at high risk of TLS.
►►

PATIENT ENGAGEMENT AND QUALITY OF LIFE
While CAR Tcell or other IEC therapies may offer
significant and durable antitumor responses for many
patients, the appropriateness of any intervention ultimately depends on patient-specific considerations. It is
important to consider potential effects on patient satisfaction and quality of life for a planned course of treatment. Additionally, all members of a caregiving team,
as well as patients themselves, must undergo sufficient
education in order to rapidly respond to any toxicities
that do occur.
Due to the relative infancy of the field, few large-scale
quality of life assessments for IEC therapies have been
performed. In the short term, quality of life generally
increases if patients experience clinically meaningful
responses to therapy. An analysis of self-
reported
outcomes from the ELIANA trial encompassing 39
patients older than 8 years of age found mean changes
from baseline for the PedsQL total and EQ-5D visual
analog scale of 13.9 and 13.7 at month 3 and 12.8 and
10.9 at month 6, respectively, supporting clinically
meaningful improvements. Additionally, the proportions of patients reporting problems with mobility,
self-care, usual activities, anxiety/depression, or pain/
discomfort were notably decreased at months 3 and 6.191
The long-term effects of CAR T cell therapy on quality
of life remain understudied. One study of self-reported
outcomes among 40 patients who completed a questionnaire containing the Patient-
Reported Outcomes
Measurement Information System (PROMIS) Scale
V.1.2 Global Health and the PROMIS-29 Profile V.2.1,
as well as 30 additional questions at a median of 3
years after CAR T cell treatment revealed that nearly
50% of patients in the cohort experienced at least
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one clinically meaningful negative neuropsychiatric
outcome, including anxiety, depression, and cognitive
difficulty.192 In that study, there was a trend toward
significance (p=0.08) for an association between acute
neurotoxicity and long-
term neuropsychiatric problems. Overall, however, no difference was observed in
mean mental health scores for patients treated with
CAR T cells and the general population.
Financial distress may cause substantial detrimental
effects on quality of life for patients with cancer,193 and
IEC therapies are among the most expensive interventions in the healthcare system. The cost of a one-
time infusion of tisagenlecleucel for pediatric ALL is
US$475,000, while the cost of tisagenlecleucel for adult
NHL, axicabtagene ciloleucel for adult NHL, and brexucabtagene autoleucel for MCL is US$373,000. Patients
may also incur additional expenses for transportation
to and from the hospital and accommodations nearby
during treatment. Despite these prices, CAR T cell
therapies have been demonstrated to be cost-effective
in terms of life-
years and quality-
adjusted life years
(QALYs) gained. A study of CAR T cell therapy versus
standard of care for pediatric patients with RR B-ALL
found that tisagenlecleucel treatment led to 10.34
discounted life-years gained and 9.28 QALYs gained,
amounting to an incremental cost-
effectiveness ratio
of approximately US$42,000 per life-year gained and
approximately US$46,000 per QALY gained compared
with clofarabine.194 An economic framework for therapy
valuation found that CAR T cell therapy for patients
with pediatric RR ALL and DLBCL generated as much
as US$6.5 billion and US$35.8 billion in social value.195
Panel recommendations
Prior to initiating therapy, patient education should
include an in-
person nursing ‘teach’ visit and a
meeting with a social worker.
►► Patient education prior to therapy should include
the difference between approved products and clinical trials, lymphodepletion chemotherapy, timing
of infusion visits, expected side effects, strategies
to manage side effects, expectations for hospital
admission, infection precautions, CRS, neurological
events, financial considerations, screening studies,
outpatient follow-
up requirements, intravenous
access on admission, timeline to produce cells, and
potential need for interim therapy.
►► Call parameters for patients undergoing outpatient
CAR T cell therapy should include fever, chills, difficulty breathing, changes in mental status, difficulty
with mobility, and vision changes.
►► Prior to CAR T cell therapy, patients should be asked
about family support.
►► Prior to initiating therapy, patients should be asked
about what type of financial/housing/transportation support they will require if they need to relocate for a period of time.

►►

20

►►

►►

Quality of life should be evaluated using validated tools such as the European Organization for
Research and Treatment of Cancer Quality of Life
Questionnaire—Core Questionnaire, the EuroQol- 5
Dimension, PROMIS, or Patient-Reported Outcome
Common Terminology Criteria for Adverse Events
(PRO-
CTCAE), depending on study protocols or
institutional policies.
For infection precautions during CAR T cell therapy,
hand hygiene should be discussed with patients and
caretakers. Seasonal influenza vaccination should
also be encouraged for all household members.

CONCLUSION
Although the toxicities associated with IEC therapy may
come on suddenly and progress rapidly, most adverse
events are treatable when prompt diagnosis is made.
A collaborative effort of different specialties including
intensive care, neurology, cardiology, emergency medicine, and infectious disease, in addition to the cell
therapy team, is critical for the successful management of toxicities. At this time, IEC therapies should
be delivered with direct involvement by cell therapists
at centers with transplant programs, accreditation
by FACT or the Joint Accreditation Committee ISCT-
Europe (JACIE), and experienced ICUs. Future studies
to add insight into the underlying pathogenesis and
pathogenomic features of IEC-
related toxicities have
the potential to further improve outcomes for patients
undergoing these potentially lifesaving therapies. As
more and more patients are treated with approved and
emerging immunotherapies, additional research will
be necessary to understand how immune-modulating
agents may potentially interact or synergize with cell-
based treatments.
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